Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.

ABSTRACT:

Background

Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable. Thus, we investigated whether allopurinol and febuxostat, the most frequently used urate-lowering treatments, have differential renoprotective effects on chronic kidney disease.

Methods

Incident users of allopurinol and febuxostat were identified from two tertiary referral centers. One-to-one propensity score matching between the allopurinol and febuxostat groups was performed. Participants were followed up until the occurrence of clinical outcomes, urate-lowering agent discontinuation, mortality, or the end of the study period, whichever occurred first. The primary outcomes were a 30% decline in estimated glomerular filtrati

SUBMITTER: Park S 

PROVIDER: S-EPMC8884483 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature